Validation and optimization of the Ion Torrent S5 XL sequencer and Oncomine workflow for BRCA1 and BRCA2 genetic testing
Metrics: PDF 3766 views | HTML 6816 views | ?
Saeam Shin1,2,*, Yoonjung Kim1,*, Seoung Chul Oh1, Nae Yu1, Seung-Tae Lee1, Jong Rak Choi1, Kyung-A Lee1
1Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
2Department of Laboratory Medicine, Hallym University College of Medicine, Kangnam Sacred Heart Hospital, Seoul, Republic of Korea
*These authors contributed equally to this work
Kyung-A Lee, email: [email protected]
Keywords: BRCA, Ion Torrent, next-generation sequencing, S5 XL, Oncomine
Received: December 22, 2016 Accepted: March 24, 2017 Published: April 03, 2017
In this study, we validated the analytical performance of BRCA1/2 sequencing using Ion Torrent’s new bench-top sequencer with amplicon panel with optimized bioinformatics pipelines. Using 43 samples that were previously validated by Illumina’s MiSeq platform and/or by Sanger sequencing/multiplex ligation-dependent probe amplification, we amplified the target with the Oncomine™ BRCA Research Assay and sequenced on Ion Torrent S5 XL (Thermo Fisher Scientific, Waltham, MA, USA). We compared two bioinformatics pipelines for optimal processing of S5 XL sequence data: the Torrent Suite with a plug-in Torrent Variant Caller (Thermo Fisher Scientific), and commercial NextGENe software (Softgenetics, State College, PA, USA). All expected 681 single nucleotide variants, 15 small indels, and three copy number variants were correctly called, except one common variant adjacent to a rare variant on the primer-binding site. The sensitivity, specificity, false positive rate, and accuracy for detection of single nucleotide variant and small indels of S5 XL sequencing were 99.85%, 100%, 0%, and 99.99% for the Torrent Variant Caller and 99.85%, 99.99%, 0.14%, and 99.99% for NextGENe, respectively. The reproducibility of variant calling was 100%, and the precision of variant frequency also showed good performance with coefficients of variation between 0.32 and 5.29%. We obtained highly accurate data through uniform and sufficient coverage depth over all target regions and through optimization of the bioinformatics pipeline. We confirmed that our platform is accurate and practical for diagnostic BRCA1/2 testing in a clinical laboratory.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.